The analysis of influence of clinical predictors on the results
of treatment with erlotinib in patients with advanced non-small
cell lung cancer.

a 2011

The analysis of influence of clinical predictors on the results of treatment with erlotinib in patients with advanced non-small cell lung cancer.

SALAJKA, František; Miloš PEŠEK; Jana KREJČÍ; Jana SKŘIČKOVÁ; Petr ZATLOUKAL et al.

Základní údaje

Originální název

The analysis of influence of clinical predictors on the results of treatment with erlotinib in patients with advanced non-small cell lung cancer.

Autoři

SALAJKA, František; Miloš PEŠEK; Jana KREJČÍ; Jana SKŘIČKOVÁ; Petr ZATLOUKAL; Leona KOUBKOVÁ; Ivona GRYGÁRKOVÁ; Michal HRNČIARIK a Michal ŠTÍCHA

Vydání

Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer, 2011

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.661

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/11:00052779

Organizační jednotka

Lékařská fakulta

ISSN

UT WoS

000291769801150

Klíčová slova anglicky

NSCLC; erlotinib; clinical predictors

Změněno: 15. 9. 2011 13:57, Mgr. Michal Petr

Anotace

V originále

Erlotinib is a tyrosine-kinase inhibitor (TKI) used for the treatment of patients with non small cell lung cancer (NSCLC) in Czech Republic since 2005. Wide use of erlotinib in patients with NSCLC enables to collect a robust data in Czech Tarceva patients registry, where are recorded all the patients treated with erlotinib in 10 centers of excellence in Czech Rep. Objective of this retrospective analysis is to compare treatment efficacy in the subgroup of patients outside the clinical studies and try to find factors influencing the treatment effect.

Citovat

SALAJKA, František; Miloš PEŠEK; Jana KREJČÍ; Jana SKŘIČKOVÁ; Petr ZATLOUKAL; Leona KOUBKOVÁ; Ivona GRYGÁRKOVÁ; Michal HRNČIARIK a Michal ŠTÍCHA. The analysis of influence of clinical predictors on the results of treatment with erlotinib in patients with advanced non-small cell lung cancer. In Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer. 2011. ISSN 1556-0864.

@proceedings{946760,
   author = {Salajka, František and Pešek, Miloš and Krejčí, Jana and Skřičková, Jana and Zatloukal, Petr and Koubková, Leona and Grygárková, Ivona and Hrnčiarik, Michal and Štícha, Michal},
   booktitle = {Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer},
   keywords = {NSCLC; erlotinib; clinical predictors},
   language = {eng},
   title = {The analysis of influence of clinical predictors on the results of treatment with erlotinib in patients with advanced non-small cell lung cancer.},
   year = {2011}
}

TY  - CONF
ID  - 946760
AU  - Salajka, František - Pešek, Miloš - Krejčí, Jana - Skřičková, Jana - Zatloukal, Petr - Koubková, Leona - Grygárková, Ivona - Hrnčiarik, Michal - Štícha, Michal
PY  - 2011
TI  - The analysis of influence of clinical predictors on the results of treatment with erlotinib in patients with advanced non-small cell lung cancer.
KW  - NSCLC
KW  - erlotinib
KW  - clinical predictors
N2  - Erlotinib is a tyrosine-kinase inhibitor (TKI) used for the treatment of patients with non small cell lung cancer (NSCLC) in Czech Republic since 2005. Wide use of erlotinib in patients with NSCLC enables to collect a robust data in Czech Tarceva patients registry, where are recorded all the patients treated with erlotinib in 10 centers of excellence in Czech Rep. Objective of this retrospective analysis is to compare treatment efficacy in the subgroup of patients outside the clinical studies and try to find factors influencing the treatment effect.
ER  -

SALAJKA, František; Miloš PEŠEK; Jana KREJČÍ; Jana SKŘIČKOVÁ; Petr ZATLOUKAL; Leona KOUBKOVÁ; Ivona GRYGÁRKOVÁ; Michal HRNČIARIK a Michal ŠTÍCHA. The analysis of influence of clinical predictors on the results of treatment with erlotinib in patients with advanced non-small cell lung cancer. In \textit{Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer}. 2011. ISSN~1556-0864.

Přehled o publikaci